Monobenzone primarily targets tyrosinase, the rate-limiting enzyme in melanin biosynthesis. Tyrosinase catalyzes the oxidation of tyrosine to DOPA and subsequently to dopaquinone, which are critical steps in the production of melanin pigments. By inhibiting tyrosinase activity, Monobenzone reduces melanin synthesis. However, unlike hydroquinone, which acts as a reversible competitive inhibitor, Monobenzone's depigmenting effect is mediated through the generation of reactive quinone metabolites that are cytotoxic to melanocytes. These metabolites haptenate melanocyte proteins, triggering an autoimmune response that leads to the permanent destruction of melanocytes. This tyrosinase-dependent irreversible melanocyte loss is the hallmark of Monobenzone's mechanism and is responsible for its permanent depigmenting effect.

In vitro studies have demonstrated that Monobenzone specifically inhibits tyrosinase activity. The compound binds to the active site of tyrosinase, blocking the enzyme's ability to catalyze the oxidation of tyrosine. However, Monobenzone's effects extend beyond simple enzyme inhibition. In melanocyte cultures, Monobenzone treatment leads to the production of reactive quinone metabolites that cause oxidative stress and damage to melanocytes. These metabolites also trigger melanosome autophagy, a process in which the cell's own melanosomes are degraded. The combination of enzyme inhibition, oxidative damage, and autophagy results in the death of melanocytes. The compound's ability to induce an immunogenic response has also been demonstrated in vitro, where haptenated melanocyte proteins can be recognized by immune cells. The molecular weight of Monobenzone is 200.23 g/mol, and its molecular formula is C13H12O2. It is soluble in alcohol, ether, and benzene but practically insoluble in water.

In vivo, Monobenzone is applied topically as a cream or ointment for the treatment of vitiligo. Clinical studies have shown that it induces progressive depigmentation of the skin over several months of treatment. The depigmentation process is permanent and irreversible, as it involves the destruction of melanocytes. Monobenzone is also used in the construction of animal models of vitiligo, where it is applied to the skin of animals to induce localized depigmentation. In these models, Monobenzone mimics the autoimmune destruction of melanocytes seen in human vitiligo, providing a valuable tool for studying the pathogenesis of the disease and testing potential therapies. The compound's ability to induce an immune response against melanocytes has also been exploited in melanoma research, where it is used to study immunotherapy approaches.

The in vitro enzyme/receptor binding assays for Monobenzone focus on its inhibition of tyrosinase activity. In these assays, tyrosinase enzyme is incubated with a substrate such as L-DOPA, and the production of dopachrome is monitored spectrophotometrically at 475 nm. Monobenzone is added at various concentrations, and the inhibition of enzyme activity is determined by measuring the decrease in dopachrome formation. The IC50 for tyrosinase inhibition can be calculated from dose-response curves. These assays confirm that Monobenzone is a potent inhibitor of tyrosinase. In addition to enzyme inhibition, the compound's ability to generate reactive metabolites and induce melanocyte cytotoxicity can be assessed in cell-based systems.

Cellular assays for Monobenzone are conducted using melanocyte cultures to evaluate its effects on cell viability and melanin production. Melanocytes are treated with Monobenzone at various concentrations, and cell viability is measured using assays such as MTT or trypan blue exclusion. Melanin content is quantified by spectrophotometric measurement after cell lysis. The induction of autophagy and apoptosis can be assessed by Western blot analysis of autophagy markers (e.g., LC3) and apoptosis markers (e.g., cleaved caspase-3). The generation of reactive oxygen species can be measured using fluorescent probes such as DCFH-DA. These cellular assays provide a comprehensive picture of Monobenzone's mechanism of action and its effects on melanocyte biology.

In vivo animal experiments for Monobenzone are conducted to establish models of vitiligo and to study the compound's depigmenting effects. In these models, Monobenzone is typically applied topically to the skin of guinea pigs, mice, or other animals. The compound is formulated as a cream or ointment and applied to a shaved area of skin daily for several weeks. Depigmentation is assessed visually and confirmed by histological analysis, which shows a reduction in the number of melanocytes and melanin content in the epidermis. These animal models are used to study the pathogenesis of vitiligo and to test potential therapies for the condition. In addition, Monobenzone-induced depigmentation models have been used to investigate the immune response against melanocytes and to evaluate immunotherapy approaches for melanoma.

Metabolism/Metabolites...Due to its low chronic toxicity, hydroquinone monobenzyl ether is predicted to be readily metabolized in the same manner as phenol.
Monobenzone has a molecular weight of 200.23 g/mol and a molecular formula of C13H12O2. It has a lipophilic character (logP ~3.2) and low aqueous solubility (251 mg/L at 25°C), making it suitable for topical formulation. The compound is very soluble in acetone, soluble in alcohol, ether, and benzene, and practically insoluble in water and petroleum hydrocarbons. For storage, it should be kept in a dry, dark place at 0-4°C for short-term storage or at -20°C for long-term storage. These physicochemical properties are important for the formulation of topical depigmenting products.

The toxicity profile of Monobenzone is characterized by its local effects on the skin. It is a potent sensitizer and can cause contact dermatitis in some individuals. The compound induces permanent, irreversible depigmentation, which is its intended therapeutic effect in vitiligo but is considered an adverse effect when used in other contexts. Systemic toxicity is limited due to the topical route of administration and the compound's poor systemic absorption. However, as with all topical agents, the risk of irritation and sensitization must be considered.

[1]. A mouse model of vitiligo induced by monobenzone. Exp Dermatol. 2013 Jul;22(7):499-501. doi: 10.1111/exd.12184.

Monobenzone is a monobenzyl ether of hydroquinone. It is a topical medication used to treat skin depigmentation. It inhibits melanin synthesis, acts as a dermatological drug, and is an sensitizer. Its function is similar to that of hydroquinone. Monobenzone is a white, almost odorless crystalline powder, readily soluble in alcohol and practically insoluble in water. It depigments mammalian skin by increasing melanin secretion from melanocytes. It may also cause melanocyte destruction and permanent depigmentation. Monobenzone is a depigmenting agent. The mechanism of action of Monobenzone is the inhibition of melanin synthesis. The physiological effect of Monobenzone is achieved through its depigmenting activity. Monobenzone is a monobenzyl ether of hydroquinone with local depigmenting activity. Although its exact depigmenting mechanism is not fully understood, the metabolites of Monobenzone appear to have cytotoxic effects on melanocytes. Furthermore, the depigmentation effect may be mediated by the inhibition of tyrosinase, an enzyme essential for melanin synthesis, leading to permanent skin depigmentation.
Drug Indications

Topical use for the treatment of skin depigmentation (vitiligo).
FDA Label

Mechanism of Action

Monobenzone is a depigmenting agent whose mechanism of action is not fully understood. It is presumed to increase melanin secretion from melanocytes. This effect is unstable and may take one to four months to appear, during which time existing melanin is lost with normal shedding of the stratum corneum. Hyperpigmented skin appears to fade faster than normal skin, and sun exposure reduces the depigmentation effect of the drug. Histological studies of skin depigmentation following topical application of Monobenzone have shown results similar to vitiligo, with intact epidermis but a lack of identifiable melanocytes.
...Interference with melanin biosynthesis. It inhibits tyrosinase, thereby preventing the conversion of tyrosine to dihydroxyphenylalanine (a precursor to melanin).
Monobenzone is an FDA-approved topical medication for the treatment of extensive vitiligo. It is the only approved monobenzyl ether of hydroquinone for this indication. The compound is marketed under the brand name Benoquin and is available as a cream formulation. Its mechanism of action involves irreversible inhibition of tyrosinase and destruction of melanocytes through the generation of reactive quinone metabolites. In addition to its clinical use, Monobenzone is widely used in research to construct animal models of vitiligo and to study melanocyte biology and immunotherapy. Despite its effectiveness, Monobenzone is not suitable for all patients due to the permanent nature of depigmentation and the potential for skin irritation and sensitization. Its use is typically reserved for patients with widespread vitiligo who have not responded to other treatments.

C13H12O2

200.237

200.083

103-16-2

7638

LUSTROUS LEAFLETS FROM WATER
WHITE CRYSTALLINE POWDER

1.2±0.1 g/cm3

359.1±17.0 °C at 760 mmHg

119-120 °C(lit.)

213.4±5.9 °C

0.0±0.8 mmHg at 25°C

1.603

2.96

1

2

3

15

167

0

O(C1C([H])=C([H])C(=C([H])C=1[H])O[H])C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H]

VYQNWZOUAUKGHI-UHFFFAOYSA-N

InChI=1S/C13H12O2/c14-12-6-8-13(9-7-12)15-10-11-4-2-1-3-5-11/h1-9,14H,10H2

4-phenylmethoxyphenol

AI3-14325; Benoquin; Monobenzone

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO : ≥ 100 mg/mL (~499.43 mM)

Solubility in Formulation 1: ≥ 2.08 mg/mL (10.39 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

---

Solubility in Formulation 2: ≥ 2.08 mg/mL (10.39 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

---

View More

Solubility in Formulation 3: ≥ 2.08 mg/mL (10.39 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

---

 (Please use freshly prepared in vivo formulations for optimal results.)